生物製藥產業市場－全球產業規模、佔有率、趨勢、機會與預測：按產品類型、治療應用、地區和競爭格局分類，2021-2031年

全球生物製藥市場預計將從 2025 年的 4,561.3 億美元大幅成長至 2031 年的 7,384.2 億美元，複合年成長率為 8.36%。

生物製藥是指生物來源或半合成的複雜藥物，例如疫苗、基因療法和重組治療性蛋白質。其成長主要源自於癌症和糖尿病等慢性疾病在全球的發生率不斷上升。此外，全球人口快速老化導致持續醫療保健需求增加，以及生物技術和製造流程的結構性進步提高了生產效率和擴充性，從而滿足了全球需求，這些因素進一步推動了生物製藥的成長。儘管成長強勁，但該行業仍面臨諸多挑戰，尤其是嚴格的監管要求和巨額的研發成本。繁雜的核准流程往往會導致市場准入延遲，並增加旨在進行全球擴張的製造商的財務風險。歐洲製藥製造商協會聯合會 (EFPIA) 報告稱，到 2025 年，北美市場將佔據顯著的集中度，預計 2024 年北美將佔全球藥品銷售額的 54.8%。這凸顯了企業在多元化的法規環境下實現平衡的國際業務擴張所面臨的挑戰。

市場促進因素

慢性病和自體免疫疾病的日益普遍是全球生物製藥市場的主要驅動力，持續推動對先進治療方法的需求，尤其是在腫瘤學和免疫學領域。隨著全球人口老化和生活方式的改變，患者群體也在發生變化，導致對特化生物製藥療法的需求日益成長，這直接轉化為製藥公司巨大的商機。例如，美國癌症協會在報告《2025年癌症事實與數據》中預測，2025年，美國將新增2,041,910例癌症病例。日益沉重的疾病負擔迫使製藥公司優先研發高附加價值的生物製藥，使有效的治療方法獲得顯著的商業性成功。默克的抗癌藥物Keytruda就是一個典型的例子，在2024會計年度的全球銷售額達到了295億美元。同時，對新型生物製藥研發的大量投資正在加速下一代藥物的研發，並推動產業成長。生物製藥公司正大力投資創新，以克服複雜的藥物研發過程，並開發出比傳統小分子藥物療效更優的先進治療方法，例如細胞療法和基因療法。這種強力的資金投入對於在嚴格的監管標準下維持產品平臺的競爭力至關重要。 2024年11月，歐洲製藥工業協會（EFPIA）報告稱，歐洲製藥業在2024年研發方面的投資金額預計將達到550億歐元。如此巨額的投資不僅將加速技術突破，還將確保持續供應滿足不斷變化的全球醫療保健需求的新產品。

市場挑戰

由於嚴格的監管要求和巨額的研發成本，全球生物製藥市場面臨巨大的成長障礙。這些財務和程序上的障礙需要大量的資金用於合規和臨床試驗，這往往會擠佔原本用於更廣泛的市場擴張的資源。遵守不同地區法規結構的複雜性延長了藥物研發週期，推遲了新治療方法的商業性上市，並縮短了可用於收回巨額投資的專利獨佔期。這種漫長的研發過程直接阻礙了市場發展勢頭，增加了財務風險並延遲了產生收入。根據國際藥品製造商協會聯合會（IFPMA）的數據，2019年至2023年間，從臨床試驗開始到完成患者招募的平均時間增加了26%。這種營運上的延誤增加了藥物上市的總成本，並限制了製造商推出多樣化產品系列的能力。因此，這些低效因素阻礙了該行業快速響應全球健康需求和維持永續經濟成長的能力。

市場趨勢

人工智慧 (AI) 和機器學習在藥物研發領域的融合正在從根本上改變生物製藥產業，使其從偶然發現轉向可預測的、數據驅動的設計。製藥公司正擴大利用生成式人工智慧平台，以前所未有的速度快速識別新標靶並最佳化分子結構，從而解決早期研究中固有的傳統低效問題。這項技術進步能夠快速模擬生物交互作用，顯著減少將有前景的候選藥物推進臨床試驗所需的時間和資金。賽諾菲與 Earendil Labs 的合作就是這項策略轉變的典型例證。根據 Fierce Biotech 2026 年 1 月報道，該合作價值高達 25.6 億美元。此次合作旨在利用人工智慧驅動的藥物研發平台開發針對自體免疫疾病的雙特異性抗體。同時，隨著主要生物製藥專利的到期，生物相似藥和生技改良藥正在獲得市場佔有率，重塑商業格局。這正在催生一個由成本效益和可近性提升所驅動的競爭環境。全球醫療系統都在鼓勵採用生物製藥以緩解不斷飆升的醫療成本，這迫使先行者要么推動創新，要么調整定價策略。這一趨勢導致生物相似藥（價格更低但療效相當）在腫瘤學和免疫學等治療領域迅速普及。生物相似藥中心在2025年5月發布的報告中引用三星Bioepis的數據，支持了生物相似藥的廣泛應用。報告指出，到2024年第四季度，生物相似藥將占美國曲妥珠單抗市場佔有率的87%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球生物製藥產業市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品類型（單株抗體、重組生長因子、純化蛋白、重組蛋白、重組荷爾蒙、疫苗、重組酵素、細胞和基因療法、合成免疫調節劑、其他）
  • 按領域分類的治療（腫瘤科、發炎和感染疾病、自體免疫疾病科、代謝性疾病科、內分泌疾病科、心血管疾病科、神經系統疾病科、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美生物製藥產業市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲生物製藥產業市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區生物製藥產業市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲生物製藥產業市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲生物製藥產業市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球生物製藥產業市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Abbvie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Johnson & Johnson
• Novartis AG
• Novo Nordisk AS
• Pfizer Inc.
• GlaxoSmithKline PLC
• F. Hoffmann-La Roche AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Biopharmaceutical Industry Market is projected to expand significantly, growing from USD 456.13 Billion in 2025 to USD 738.42 Billion by 2031, demonstrating an 8.36% compound annual growth rate. Biopharmaceuticals, defined as intricate medicinal products derived from or semi-synthesized from biological sources-including vaccines, gene therapies, and recombinant therapeutic proteins-are primarily driven by the escalating global incidence of chronic conditions such as cancer and diabetes. This growth is further fueled by a rapidly aging worldwide population requiring sustained medical care and by structural advancements in biotechnology and manufacturing, which enhance production efficiency and scalability to meet global demand.Despite this robust growth, the industry encounters substantial obstacles, notably stringent regulatory requirements and the prohibitive costs associated with research and development. Navigating varied and complex approval processes frequently delays market entry and elevates financial risks for manufacturers aiming for global reach. A significant market concentration is observed in North America, which accounted for 54.8% of estimated world pharmaceutical sales in 2024, as reported by the European Federation of Pharmaceutical Industries and Associations in 2025. This highlights the difficulty companies face in achieving balanced international commercial expansion across diverse regulatory environments.

Market Driver

The increasing prevalence of chronic and autoimmune diseases serves as a primary driver for the Global Biopharmaceutical Industry Market, generating persistent demand for advanced therapeutics, particularly in oncology and immunology. As patient demographics shift due to an aging global populace and evolving lifestyles, the need for specialized biologic treatments intensifies, directly translating into substantial revenue opportunities for manufacturers. For instance, the American Cancer Society projected 2,041,910 new cancer cases in the United States in 2025, as noted in its 'Cancer Facts & Figures 2025' report. This mounting disease burden compels pharmaceutical companies to prioritize high-value biologic interventions, leading to significant commercial success for effective treatments, exemplified by Merck's oncology drug Keytruda achieving global sales of $29.5 billion in the 2024 financial year.Concurrently, significant investments in research and development for novel biologics are propelling industry growth by facilitating the creation of next-generation medicines. Biopharmaceutical companies are heavily investing in innovation to navigate complex drug discovery processes and develop sophisticated modalities like cell and gene therapies, which offer superior efficacy compared to traditional small molecules. This strong financial commitment is crucial for maintaining a competitive product pipeline amid rigorous regulatory standards. The European Federation of Pharmaceutical Industries and Associations reported in November 2024 that the industry invested an estimated €55,000 million in R&D in Europe during 2024. Such substantial capital infusion not only accelerates technological breakthroughs but also ensures a continuous supply of new products necessary to address evolving global healthcare demands.

Market Challenge

The Global Biopharmaceutical Industry Market faces significant impediments to growth due to stringent regulatory requirements and the exorbitant costs associated with research and development. These financial and procedural barriers necessitate substantial capital allocation towards compliance and clinical testing, often diverting resources from broader market expansion initiatives. The intricate nature of navigating disparate regulatory frameworks across various regions extends the drug development lifecycle, delaying the commercial launch of new therapies and diminishing the period of patent exclusivity available to recoup massive investments.This prolonged development process directly hinders market momentum by increasing financial risk and deferring revenue generation. According to the International Federation of Pharmaceutical Manufacturers and Associations, the average time from clinical trial initiation to patient enrollment closure rose by 26% between 2019 and 2023. Such operational delays inflate the overall cost of bringing medicines to market and restrict manufacturers' capacity to launch diverse product portfolios. Consequently, these inefficiencies impede the industry's ability to promptly address global health needs and maintain consistent economic growth.

Market Trends

The integration of Artificial Intelligence and Machine Learning in drug discovery is fundamentally transforming the biopharmaceutical industry, shifting from chance-based findings to predictive, data-driven design. Pharmaceutical companies are increasingly employing generative AI platforms to rapidly identify novel targets and optimize molecule structures with unprecedented speed, thereby addressing the historical inefficiencies inherent in early-stage research. This technological evolution enables swift simulation of biological interactions, substantially reducing the time and capital required to advance promising candidates to clinical trials. A notable example of this strategic shift is Sanofi's collaboration with Earendil Labs, valued at up to $2.56 billion, announced in January 2026 by Fierce Biotech, aimed at leveraging an AI-powered discovery platform for developing bispecific antibodies against autoimmune diseases.Simultaneously, the increasing market penetration of biosimilars and biobetters is reshaping the commercial landscape as key biologic patents expire, fostering a competitive environment driven by cost-efficiency and enhanced accessibility. Healthcare systems worldwide are encouraging the adoption of these follow-on biologics to alleviate rising healthcare expenditures, compelling originator companies to innovate or adjust their pricing strategies. This dynamic leads to rapid adoption rates for biosimilars in therapeutic areas such as oncology and immunology, where they offer comparable efficacy at reduced costs. Illustrating this widespread acceptance, The Center for Biosimilars reported in May 2025, citing Samsung Bioepis data, that biosimilars had captured 87% of the trastuzumab market in the United States by the fourth quarter of 2024.

Key Market Players

• Abbvie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Johnson & Johnson
• Novartis AG
• Novo Nordisk AS
• Pfizer Inc.
• GlaxoSmithKline PLC
• F. Hoffmann-La Roche AG

Report Scope

In this report, the Global Biopharmaceutical Industry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biopharmaceutical Industry Market, By Product Type

• Monoclonal Antibodies
• Recombinant Growth Factors
• Purified Proteins
• Recombinant Proteins
• Recombinant Hormones
• Vaccines
• Recombinant Enzymes
• Cell and Gene Therapies
• Synthetic Immunomodulators
• Others

Biopharmaceutical Industry Market, By Therapeutic Application

• Oncology
• Inflammatory and Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders
• Cardiovascular Diseases
• Neurological Diseases
• Other

Biopharmaceutical Industry Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biopharmaceutical Industry Market.

Available Customizations:

Global Biopharmaceutical Industry Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biopharmaceutical Industry Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines, Recombinant Enzymes, Cell and Gene Therapies, Synthetic Immunomodulators, Others)
  • 5.2.2. By Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Biopharmaceutical Industry Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Therapeutic Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Biopharmaceutical Industry Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Therapeutic Application
  • 6.3.2. Canada Biopharmaceutical Industry Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Therapeutic Application
  • 6.3.3. Mexico Biopharmaceutical Industry Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Therapeutic Application

7. Europe Biopharmaceutical Industry Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Therapeutic Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Biopharmaceutical Industry Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Therapeutic Application
  • 7.3.2. France Biopharmaceutical Industry Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Therapeutic Application
  • 7.3.3. United Kingdom Biopharmaceutical Industry Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Therapeutic Application
  • 7.3.4. Italy Biopharmaceutical Industry Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Therapeutic Application
  • 7.3.5. Spain Biopharmaceutical Industry Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Therapeutic Application

8. Asia Pacific Biopharmaceutical Industry Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Therapeutic Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Biopharmaceutical Industry Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Therapeutic Application
  • 8.3.2. India Biopharmaceutical Industry Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Therapeutic Application
  • 8.3.3. Japan Biopharmaceutical Industry Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Therapeutic Application
  • 8.3.4. South Korea Biopharmaceutical Industry Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Therapeutic Application
  • 8.3.5. Australia Biopharmaceutical Industry Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Therapeutic Application

9. Middle East & Africa Biopharmaceutical Industry Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Therapeutic Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Biopharmaceutical Industry Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Therapeutic Application
  • 9.3.2. UAE Biopharmaceutical Industry Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Therapeutic Application
  • 9.3.3. South Africa Biopharmaceutical Industry Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Therapeutic Application

10. South America Biopharmaceutical Industry Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Therapeutic Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Biopharmaceutical Industry Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Therapeutic Application
  • 10.3.2. Colombia Biopharmaceutical Industry Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Therapeutic Application
  • 10.3.3. Argentina Biopharmaceutical Industry Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Therapeutic Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Biopharmaceutical Industry Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbvie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Amgen Inc.
• 15.3. Bristol-Myers Squibb Company
• 15.4. Eli Lilly and Company
• 15.5. Johnson & Johnson
• 15.6. Novartis AG
• 15.7. Novo Nordisk AS
• 15.8. Pfizer Inc.
• 15.9. GlaxoSmithKline PLC
• 15.10. F. Hoffmann-La Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer